AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 31 min read$GMAB

Genmab A/S (GMAB) Reports 45.9% ORR, 9.5m PFS for Rina-S in Platinum-Resistant Ovarian Cancer

Genmab reported Phase 1/2 trial results for Rina-S in platinum-resistant ovarian cancer, showing 45.9% ORR, 12.1m mDOR, and 9.5m mPFS among 109 patients. The drug showed activity regardless of FRα expression or prior mirvetuximab treatment, according to the company.

Original reporting
tradingview.com
Published Oct 3, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 7:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab A/S (GMAB) Reports 45.9% ORR, 9.5m PFS for Rina-S in Platinum-Resistant Ovarian Cancer — source image
Source · tradingview.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The disclosed ORR and PFS metrics are markedly higher than historical benchmarks, suggesting a competitive advantage.

02

Market read

First‑time release of strong mid‑stage trial data for an ADC; likely to move Genmab's stock and influence biotech sector sentiment.

03

What to watch

Potential competition from other FRα‑targeted agents and the need for larger patient cohorts.

Relevance 9/10Novelty 9/10Timing: today

Background

Genmab is a Copenhagen‑based biotech focused on antibody‑drug conjugates (ADCs). The Rina‑S candidate targets folate receptor‑alpha (FRα) in ovarian cancer.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab disclosed Phase 1/2 trial results showing 45.9% ORR and 9.5‑month median PFS for Rina‑S in platinum‑resistant ovarian cancer.

Expected impact

likely upward pressure as investors price in the strong efficacy signal

Evidence & confidence

First disclosure of robust efficacy metrics for a key ADC; biotech stocks typically react sharply to such data.

Market effects

Sector

strengthens the ADC oncology pipeline narrative, may benefit peer biotech firms developing similar therapies

Regional

European biotech markets could see modest gains on the back of the data

Global

global investors in oncology biotech may adjust exposure

Counterpoint

What could challenge this read

Data may not translate to regulatory approval; investors could be cautious until Phase 3 results.

Key entities

  • company
    Genmab A/S

    Danish biotech developing ADCs, listed on Nasdaq as GMAB.

  • product
    Rina‑S

    ADC candidate for platinum‑resistant ovarian cancer.

Read at source← All news

Related articles

OCT 3
$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

finanznachrichten.de3 min
OCT 3
$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

investing.com2 min